Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Risk factors contributing to urinary protein expression resulting from bevacizumab combination chemotherapy.

Teramachi H, Shiga H, Komada N, Tamura K, Yasuda M, Umeda M, Tachi T, Goto C, Tsuchiya T.

Pharmazie. 2013 Mar;68(3):217-20.

PMID:
23556342
2.

[Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer].

Horinouchi Y, Sakurada T, Nakamura T, Tajima S, Nishisako H, Abe S, Teraoka K, Kujime T, Kawazoe K, Minakuchi K.

Yakugaku Zasshi. 2011;131(8):1251-7. Japanese.

3.

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups.

N Engl J Med. 2012 Jan 26;366(4):299-309. doi: 10.1056/NEJMoa1111065.

4.

Bevacizumab and ovarian cancer.

Sato S, Itamochi H.

Curr Opin Obstet Gynecol. 2012 Feb;24(1):8-13. doi: 10.1097/GCO.0b013e32834daeed. Review.

PMID:
22123222
5.

The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.

Budai B, Nagy T, Láng I, Hitre E.

Angiogenesis. 2013 Jan;16(1):113-21. doi: 10.1007/s10456-012-9303-z. Epub 2012 Sep 6.

PMID:
22956187
6.

Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.

Tassinari D, Sartori S, Papi M, Drudi F, Castellani C, Carloni F, Tombesi P, Lazzari-Agli L.

Oncology. 2011;80(5-6):350-8. doi: 10.1159/000328781. Epub 2011 Jul 27.

PMID:
21791945
7.

Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients.

Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR.

Cancer Chemother Pharmacol. 2014 Jun;73(6):1197-204. doi: 10.1007/s00280-014-2456-2. Epub 2014 Apr 8.

PMID:
24710627
8.

Bevacizumab increases risk for severe proteinuria in cancer patients.

Wu S, Kim C, Baer L, Zhu X.

J Am Soc Nephrol. 2010 Aug;21(8):1381-9. doi: 10.1681/ASN.2010020167. Epub 2010 Jun 10. Review.

9.

Feasibility and tolerability of bevacizumab in children with primary CNS tumors.

Reismüller B, Azizi AA, Peyrl A, Heinrich M, Gruber-Olipitz M, Luckner D, Rothschild KV, Slavc I.

Pediatr Blood Cancer. 2010 May;54(5):681-6. doi: 10.1002/pbc.22409.

PMID:
20066713
10.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH.

N Engl J Med. 2006 Dec 14;355(24):2542-50. Erratum in: N Engl J Med. 2007 Jan 18;356(3):318.

11.

Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.

Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW.

J Clin Oncol. 2008 Nov 10;26(32):5254-60. doi: 10.1200/JCO.2008.17.7857. Epub 2008 Oct 14.

PMID:
18854565
12.

Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients.

Tamiya A, Yamazaki K, Boku N, Machida N, Kojima T, Taku K, Yasui H, Fukutomi A, Hironaka S, Onozawa Y.

Int J Clin Oncol. 2009 Dec;14(6):513-7. doi: 10.1007/s10147-009-0911-6. Epub 2009 Dec 5.

PMID:
19967487
13.

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

Shih T, Lindley C.

Clin Ther. 2006 Nov;28(11):1779-802. Review.

PMID:
17212999
14.
15.

Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer.

Kanai M, Ishiguro H, Mori Y, Kitano T, Nishimura T, Matsumoto S, Yanagihara K, Chiba T, Toi M.

Br J Cancer. 2011 Nov 22;105(11):1693-6. doi: 10.1038/bjc.2011.398. Epub 2011 Oct 27.

16.

Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?

Richardson DL, Backes FJ, Hurt JD, Seamon LG, Copeland LJ, Fowler JM, Cohn DE, O'Malley DM.

Gynecol Oncol. 2010 Jul;118(1):47-51. doi: 10.1016/j.ygyno.2010.01.011. Epub 2010 Apr 10.

PMID:
20382413
17.

A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.

Jones SF, Spigel DR, Yardley DA, Thompson DF, Burris HA 3rd.

Clin Adv Hematol Oncol. 2011 Nov;9(11):845-52.

PMID:
22252616
18.

Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.

Teoh D, Secord AA.

Int J Gynecol Cancer. 2012 Mar;22(3):348-59. doi: 10.1097/IGC.0b013e31823c6efd. Review.

PMID:
22266932
19.

MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC.

Dansin E, Cinieri S, Garrido P, Griesinger F, Isla D, Koehler M, Kohlhaeufl M.

Lung Cancer. 2012 Jun;76(3):373-9. doi: 10.1016/j.lungcan.2011.11.020. Epub 2012 Jan 10.

PMID:
22236866
20.

Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.

Stevenson JP, Langer CJ, Somer RA, Evans TL, Rajagopalan K, Krieger K, Jacobs-Small M, Dyanick N, Milcarek B, Coakley S, Walker S, Eaby-Sandy B, Hageboutros A.

Cancer. 2012 Nov 15;118(22):5580-7. doi: 10.1002/cncr.27576. Epub 2012 Apr 27.

Supplemental Content

Support Center